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Background: The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not
resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600
(p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partial response. Therefore, the
precise identification of the underlying somatic mutations is essential. Herein, we evaluate the sensitivity, specificity
and feasibility of six different methods for the detection of BRAF mutations.
Methods: Samples harboring p.V600E mutations as well as rare mutations in BRAF exon 15 were compared to
wildtype samples. DNA was extracted from formalin-fixed paraffin-embedded tissues by manual micro-dissection
and automated extraction. BRAF mutational analysis was carried out by high resolution melting (HRM) analysis,
pyrosequencing, allele specific PCR, next generation sequencing (NGS) and immunohistochemistry (IHC). All
mutations were independently reassessed by Sanger sequencing. Due to the limited tumor tissue available different
numbers of samples were analyzed with each method (82, 72, 60, 72, 49 and 82 respectively).
Results: There was no difference in sensitivity between the HRM analysis and Sanger sequencing (98%). All
mutations down to 6.6% allele frequency could be detected with 100% specificity. In contrast, pyrosequencing
detected 100% of the mutations down to 5% allele frequency but exhibited only 90% specificity. The allele specific
PCR failed to detect 16.3% of the mutations eligible for therapy with vemurafenib. NGS could analyze 100% of the
cases with 100% specificity but exhibited 97.5% sensitivity. IHC showed once cross-reactivity with p.V600R but was a
good amendment to HRM.
Conclusion: Therefore, at present, a combination of HRM and IHC is recommended to increase sensitivity and
specificity for routine diagnostic to fulfill the European requirements concerning vemurafenib therapy of
melanoma patients.
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The v-raf murine sarcoma viral oncogene homolog B1
(BRAF) is one of three RAF genes (rapidly accelerated
fibrosarcoma A, B, C) localized on chromosome 7q34.
This gene encodes a cytoplasmic serine-threonine pro-
tein kinase of the RAF family. RAF kinases are part of
the mitogen-activated protein (MAP) kinase pathway in-
volved in cell growth, survival and differentiation [1].
BRAF mutations play an important role in 40 – 70% of
malignant melanomas, 45% of papillary thyroid cancers
and 10% of colorectal cancers besides ovarian, breast
and lung cancers [2-4].
According to the COSMIC database (Catalogue Of
Somatic Mutations In Cancer, Dec 2013 [5]) 44% of the
melanomas harbor BRAF mutations and 97.1% of these
mutations are localized in codon 600 of the BRAF gene [6].
The most common variation is a substitution of valine to
glutamic acid at codon 600 (c.1799 T >A, p.V600E or
c.1799_1800TG > AA, p.V600E2; frequency 84.6%). Less
common mutations are substitutions of valine to lysine
(c.1798_1799GT > AA, p.V600K; frequency 7.7%), to
arginine (c.1798_1799GT > AG, p.V600R; 1.0%), to leu-
cin (c.1798G > A, p.V600M; 0.3%) or to aspartic acid
(c.1799_1780TG >AT, p.V600D; 0.1%), mutations affect-
ing codon 597 (p.L597; 0.5%), codon 594 (p.D594; 0.4%)
and mutations in codon 601 resulting in the exchange of
lysine to glutamic acid (c.1801A >G, p.K601E; 0.7%).
The approval of vemurafenib (PLX 4032, Roche Mo-
lecular Systems, Pleasanton, CA) in the US 2011 and in
Europe 2012 improved the therapy of not resectable or
metastatic melanoma. Vemurafenib exhibits an approxi-
mately 30-fold selectivity for p.V600E mutated compared
to wildtype BRAF melanomas. In addition, patients car-
rying a p.V600K mutation included in the BRIM-3 study
showed response to this inhibitor [7]. In a phase I trial, a
70% response rate to vemurafenib among 32 genotype
selected metastatic melanoma patients was observed [8].
Recent in vitro and in vivo experiments indicate that
vemurafenib might have an effect in patients with rare
mutations in codon 600 of the BRAF gene [9-11] as for
instance p.V600D or p.V600R [12,13]. Furthermore, dab-
rafenib (GSK2118436), another selective BRAF inhibitor
[14] shows good clinical response rates not only for
patients with p.V600E or p.V600K mutations but also
in patients carrying a p.V600R, p.V600M or a double
p.[V600E(;)V600M] mutation [15,16] giving new therapy
options for melanoma patients with rare BRAF mutations.
The FDA approved vemurafenib with the cobas® BRAF
V600 test (Roche) as companion diagnostic tool. The Euro-
pean Medicine Agency`s (EMA) Committee for Human
Medicinal Products (CHMP) approved vemurafenib in
February 2012 with two main differences to the FDA
approval: a companion diagnostic test was not defined and
treatment option is given for patients with melanomascarrying any mutation in codon 600 of the BRAF gene.
Because a mutation in codon 600 determines eligibility for
BRAF inhibitor treatment, several molecular screening
methods have been developed. However, the level of
validation and characterization of the performance features
is not defined.
The aim of this study was to evaluate several parame-
ters such as sensitivity and feasibility of different methods
for the BRAF mutation analysis. Here, we compare the
allele specific PCR done by the cobas® BRAF V600 test,
the pyrosequencing using the therascreen® BRAF Pyro Kit
(Qiagen), the high resolution melting (HRM) analysis,
the immunohistochemistry (IHC), the next generation
sequencing (NGS) approach and the bidirectional
Sanger sequencing with regard to their sensitivity, specifi-
city, costs, amount of work, feasibility and limitations. To
our knowledge, this is the only study comparing these five
PCR-based methods with IHC.Methods
Samples
A total of 82 tumor samples were collected in the years
2010 until 2013 under approved ethical protocols com-
plied with the Ethics Committee of the University of
Cologne (Germany) and with informed consent from
each patient. Of these, 63 samples were melanomas, 11
were lung adenocarcinomas and eight were colorectal
carcinomas.
Tumors were diagnosed by an experienced pathologist
(H. U. S., L. T.) and tumor content and pigmentation
were defined. All samples were analyzed with Sanger
sequencing as gold standard and the in-house method
high resolution melting (HRM) analysis. The other
methods were evaluated with a smaller number of
samples due to the limited amount of tumor tissue
available. Special attention was paid to the fact that each
mutation type was once analyzed with each method.
Overall 40 samples were at least analyzed with each of
the six evaluated methods.DNA isolation
All samples were fixed in neutral-buffered formalin prior to
paraffin embedding (FFPE-samples). On a haematoxylin-
eosin stained slide tumor areas were selected by a patholo-
gist (H.U.S.) and DNA was extracted from corresponding
unstained 10 μm thick slides by manual micro-dissection.
The DNA was isolated by automated extraction using the
BioRobot M48 (Qiagen, Hilden, GER) following the manu-
facturer’s protocols. Quality and quantity of isolated DNA
was assessed by agarose gel electrophoresis, by a Nanodrop
2000c spectrophotometer (PeqLab, Erlangen, GER) or in
the case of next generation sequencing with the Qubit®
Fluorometer (Life Technologies, Carlsbad, USA).
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High resolution melting (HRM) analysis was set up
using 10 ng of genomic DNA, 3.5 mM MgCl2, 1× Light-
Cycler 480 High Resolution Melting Master and 200 nM
of each primer in a final reaction volume of 20 μl.
Primer sequences were as follows: forward 5’- ATG
CTT GCT CTG ATA GGA AAA TGA -3’ and reverse
5’- ATC CAG ACA ACT GTT CAA ACT -3’ with an
annealing temperature of 59°C. Analyses were performed
in duplicates using the LightCycler 480 platform (Roche
Diagnostics, Mannheim, GER). Each run included a wild-
type control and a mutant, p.V600E, control for nor-
malization. Results were analyzed by Gene Scanning
software with normalized, temperature-shifted melting
curves displayed as difference plot. Samples showing a
melting behavior differing from the wildtype control but
not that of a mutant sample were considered as border-
line samples. These samples were retested by direct
Sanger sequencing of HRM products.Sanger sequencing
Sanger sequencing was performed on the same amplicons
as used for HRM analysis. 5 μl of PCR products were
purified with exonuclease I and Fast-AP (Thermo
Fisher Scientific, Waltham, USA) for 15 min at 37°C
and 15 min by 80°C. A sequencing reaction was set up
with 1 μl of purified PCR products and the BigDye®
Terminator v1.1 Cycle Sequencing Kit (Life Technolo-
gies) following the manufacturer’s instructions. The
BigDye XTerminator® Purification Kit (Life Technolo-
gies) was used for the purification of the DNA sequen-
cing reactions removing non-incorporated BigDye®
terminators and salts. Solution was incubated for 30 min
with agitation of 1800 rpm. Sequencing analyses were car-
ried out on the eight capillary 3500 Genetic Analyzer (Life
Technologies).Next generation sequencing
Targeted next generation sequencing (NGS) was per-
formed on 72 FFPE samples. Isolated DNA (<0.5 –
97.6 ng/μl) was amplified with an in-house specified,
customized Ion AmpliSeq Primer Pool. The panel com-
prises 102 amplicons of 14 different genes including exon
11 and 15 of the BRAF gene. PCR products were ligated
to adapters and enriched for target regions using the Ion
AmpliSeq PanelTM Library kit according to manufacturer’s
instructions (Life Technologies). The generated libraries
were equimolar pooled for amplicon sequencing to a
concentration of 20 nM of each sample to counterbalance
differences in sample quality. Sequencing was performed
on an Illumina MiSeq benchtop sequencer (Illumina, San
Diego, USA). Results were visualized in the Integrative
Genomics Viewer (IGV) [6] and manually analyzed. A 5%cutoff for variant calls was used and results were only
interpreted if the coverage was >100.
Pyrosequencing
Pyrosequencing was performed with the therascreen®
BRAF Pyro Kit (Qiagen) detecting certain mutations in
codon 600 of the BRAF gene according to manufac-
turer’s instructions. 1 μl of each isolated DNA was ana-
lyzed per run. Pyrosequencing was performed on the
PyroMark Q24 platform (Qiagen) using the PyroMark
Gold Q24 reagents. Pyrograms were generated with the
PyroMark Q24 software (v. 2.0.6.) and data were analyzed
manually or with a plug-in tool provided by Qiagen.
Sequences surrounding the site of interest served as
normalization and reference peaks for quantification and
quality control. Dispensation order was as follows: 5’-
GCT ACT GTA GCT AGT ACG AAC TCA-3’. Two dif-
ferent “sequence to analyze” were used: 5’- YAY TGT
AGC TAG ACS AAA AYC ACC -3’ or 5’- CHC TGT
AGC TAG ACS AAA ATY ACC -3’ for manual analysis.
Samples with 5% mutated alleles or more were scored as
mutation positive.
Allele specific PCR
For the allele specific PCR the cobas® BRAF V600 test was
utilized. DNA was isolated with the in-house method. Fol-
lowing the manufacturer’s instructions, 5 ng/μl DNA of
each sample were analyzed on the cobas® z 480 system. If
the concentration of the extracted DNA was too low, the
maximum DNA volume of 25 μl was used. The results
were displayed automatically as report by the cobas® z 480
software.
Immunohistochemistry
Anti-BRAF p.V600E immunohistochemical staining was
performed using the specific monoclonal mouse anti-
body VE1 (Spring Bioscience, Pleasanton, CA, USA;
purchased from Zytomed Systems, Berlin, Germany).
Dewaxing, heat induced epitope retrieval with citrate
buffer, antibody incubation (dilution 1:50) and counter-
staining were carried out on a BOND Max immunostai-
ner by using Bond Epitope Retrieval Solution 1 and the
Bond Polymer Refine Detection kit (Menarini, Berlin,
Germany). Immunohistochemical staining was carried
out within 2 weeks after cutting the 4 μm sections.
Staining results were scored from 0 to 3+ by a senior
pathologist (H. U. S. or I. G.) blinded to the results of
molecular analysis. The staining was considered as posi-
tive for p.V600E staining (2+ and 3+) when the majority
of viable tumor cells showed clear cytoplasmic staining.
Negative staining results were interpreted when there
was no or only slight staining, staining of only single
cells or of monocytes and macrophages (0 and 1+).
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Precise identification of genomic alterations is essential
for personalized therapy in cancer. Concerning melan-
oma, particularly patients carrying a mutation in codon
600 of the BRAF gene respond to vemurafenib [7,17]. As
no companion diagnostic test for this drug is prescribed
in Europe, we aimed at evaluating a sensitive and specific
molecular method for BRAF mutation analysis by compar-
ing high resolution melting (HRM) analysis, pyrosequenc-
ing (therascreen® BRAF Pyro Kit (Qiagen)), allele specific
PCR (cobas® BRAF V600 test (Roche)), Sanger sequencing,
next generation sequencing (NGS) and immunohisto-
chemistry (IHC).
82 tumor samples (63 melanomas, 11 lung adenocarcinomas
and eight colorectal carcinomas) evaluated during
routine diagnostics from 2010 – 2013 and covering a
wide range of different mutations as well as wildtype
samples were subjected to analysis. Because of limited
tumor tissue available we were not able to analyze all
samples with each method but we paid attention to
the fact that each mutation type was once analyzed
with each method. At least, 40 samples were analyzed
with all six evaluated methods. Lung adenocarcinomas
as well as colorectal carcinomas were included into
this study to get a broader spectrum of mutations.
Hereby, the frequency of mutations other than p.V600E
is significantly higher than in melanoma [18-20]. BRAF
mutations were mainly found in codon 600, codon
469 and codon 594 of non-small-cell lung cancer
(NSCLC) samples [21]. Furthermore, therapies targeting
BRAF mutant tumors have recently been identified in
NSCLC [22,23].
Tumor content and pigmentation was assessed by
an experienced pathologist (H. U. S. or I. G.). The
proportion of tumor cells ranged from 15 - 100%
(Additional file 1) and pigmentation was scored as no
(<5% of evaluated melanoma cells), low (5 - 49%) and
high pigmentation (>50%).
High resolution melting analysis and Sanger sequencing
Using the high resolution melting (HRM) method and
Sanger sequencing, 81 of 82 samples could be amplified
(Additional file 1) and analyzed using the same PCR
products. Cases were considered as mutated using HRM
if a significant difference of the fluorescence level was
detected that was outside the range of variation of the
wildtype control. Samples in between wildtype control
and a mutant melting behavior were considered as bor-
derline results. All mutated as well as borderline samples
were subjected to Sanger sequencing to determine the spe-
cific mutation type. The assay was set up with an amplicon
of 163 base pairs and is therefore able to detect all hotspot
mutations as well as rare mutations in the entire exon 15
(codon 582 to 620) of BRAF (specificity 100%). This is inconcordance with the studies of Colomba et al. [24] and
Tol et al. [25]. Figure 1 displays representative difference
plots for BRAF p.V600E (D), p.V600K (E) and p.V600R (F)
mutations. p.V600E mutation (control, shown in red) can
be clearly distinguished from p.V600K mutation (shown in
green) and p.V600R (shown in blue). Furthermore, electro-
pherograms with common mutations in codon 600 of the
BRAF gene analyzed by Sanger sequencing are shown:
p.V600E (A), p.V600K (B) and p.V600R (C).
Only one sample with p.V600E mutation could neither
be analyzed by Sanger sequencing nor by HRM because
of amplification failure (1.2%). Others have shown, that
melanin binds to and interferes with DNA polymerases
resulting in invalid test results [26]. But this case had a
tumor content of 80% and showed no pigmentation.
Therefore, the failure of amplification of the 163 bp frag-
ment for Sanger sequencing and HRM is rather due
to the high degradation of FFPE-used material than to
pigmentation. This high degradation of FFPE used ma-
terial can also explain the higher Sanger sequencing
failure rate described in other studies using a larger PCR
product for analysis [24,27].
The sensitivity of Sanger sequencing is described in
the literature as 20% mutated alleles in a background of
wildtype alleles [28], but in the present study, we were
able to detect 6.6% mutated alleles (Table 1, Additional
file 1). Figure 2 shows six electropherograms of samples
analyzed in this study with different allele frequencies ac-
cording to next generation sequencing (A: 0%, B: 6.6%, C:
15%, D: 33%, E: 62% and F: 87%). B) shows that a sample
with 6.6% allele frequency can be distinguished from a
wildtype sample (A) and that an allele frequency of 15%
can be clearly detected as p.V600E mutation using Sanger
sequencing. HRM analysis has an even lower detection
limit of 6.3% mutated alleles as reported by our group pre-
viously [29]. Carbonell et al. showed an even lower detec-
tion limit ranging from 1 – 5% [27]. This was also
supported by Balic et al. [30] who showed that analyzing
DNA methylation 1% methylated DNA in the background
of unmethylated DNA could be reproducibly detected in
fresh frozen as well as in FFPE samples.
99% of all mutations could be detected by HRM as
well as by Sanger sequencing. Case 30 could be ampli-
fied and was wildtype using Sanger sequencing, HRM
and the cobas® BRAF V600 test but exhibited a p.V600E
BRAF mutation with an allele frequency between 5 and
2% using pyrosequencing and NGS. Immunohistochem-
istry was scored positively as 2+. Tumor content of this
sample was 30% with a high pigmentation rate (case 30,
Figure 3, Additional file 1). At least for Sanger sequen-
cing, it was already reported that the tumor content may
have influence on the sensitivity. Tol et al. demonstrated
that the analysis of tumor samples containing more than
30% percent of tumor cells increased the sensitivity of
Figure 1 Representative results for BRAF exon 15 mutation analysis. Sanger sequencing (A - C), high resolution melting (HRM) analysis
(D - F), pyrosequencing (Pyro) (G - I) and immunohistochemistry (IHC) (J-L) are compared: The first column shows exemplarily p.V600E
mutations, the second p.V600K mutations and the third column p.V600R mutations. In HRM, normalized and temperature shifted difference plots
showing wildtype control in blue and mutant control in red. HRM can distinguish between p.V600E (red) and p.V600K (green) and p.V600R (light blue).
Pyrosequencing was performed in the reverse direction with the sequence to analyze 5’- YAY TGT AGC TAG ACS AAA AYC ACC -3’. All three mutations
can be detected. Immunohistochemistry shows a strong staining for p.V600E (J) but is negative for p.V600K (K) in representative melanoma sample.
Pigmentation has to be clearly distinguished from a positive p.V600E staining (K). Cross reactivity was observed for p.V600R mutation (L) in a colorectal
carcinoma sample. A: adenine, C: cytosine, G: guanine, T: thymine, V: valine, E: glutamic acid, K: lysine, R: arginine.
Table 1 Summary of the properties of the evaluated methods
HRM Pyro Cobas IHC NGS Sanger
CE mark No No Yes No No No
Limit of detection [%] 6.6 5 7 5 2 6.6
Detection of rare mutations Yes Yes- downstream of codon 600 No- 4 different mutations No- p.V600E Yes Yes
Specificity [%] 100 90 98.3 98 100 100
Turnaround time 1 day 2 days 1 day 1 day 3 - 5 days 2 - 3 days
Costs Low High Medium Low Very high Medium
HRM: high resolution melting analysis; Pyro: pyrosequencing with the therascreen® BRAF Pyro Kit; cobas: cobas® BRAF V600 test; IHC: immunohistochemistry;
NGS: next generation sequencing on the MiSeq platform; Sanger: Sanger sequencing.
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Figure 2 BRAF p.V600E mutation analysis of formalin-fixed paraffin-embedded tumor samples using Sanger sequencing.
Electropherograms showing that Sanger sequencing is not only able to detect mutations with high mutant allele frequency (D - F) but also
mutations with rather low mutant allele frequency (B and C) compared to a wildtype sample (A). Even 6.6% of BRAF p.V600E allele could be
detected. A: adenine, C: cytosine, G: guanine, T: thymine, T: threonin, V: valine, K: lysine.
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tal cancer samples [25].
Case 67, showing twice a borderline result in HRM, re-
vealed a substitution from guanine to adenine in only one
of four Sanger sequencing reactions. The cobas® BRAF
V600 test was also negative. Therefore, this substitution
was considered to be a fixation artifact and the case was
classified as wildtype. A pitfall of all PCR based methods
amplifying DNA from FFPE tissues is this occurrence offixation artifacts [31,32]. To exclude such false-positive re-
sults, we highly recommend performing PCR amplifica-
tion in duplicates prior to mutation analysis.
Pyrosequencing
Pyrosequencing is a real-time sequencing by synthesis
approach and allows the quantification of mutated
alleles. The therascreen® BRAF Pyro Kit for exon 15 of
BRAF is specific for mutations in codon 600 with a
Figure 3 Melanoma sample showing different results of the BRAF p.V600E mutational analysis (case 30). Sanger sequencing as well as
high resolution melting analysis show wildtype results (A and B, respectively). Pyrosequencing analysis resulted in a p.V600E mutation with
a 5% mutant allele frequency having low relative fluorescent units of almost 30 (C). This result is confirmed by immunohistochemistry (D).
Next generation sequencing resulted in a 2% mutant allele frequency with a coverage rate of 181 (E).
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background of wildtype alleles according to manufac-
turer’s reference. In addition, recent reports show that
even rare mutations in codon 600 can be detected using
pyrosequencing with a customer designed assay set
up [24,33]. In our preselected cohort the minimum of
mutated alleles detected with pyrosequencing was 5%
(Table 1 and Additional file 1). This is in concordance
with Tsiatis et al. showing as well a detection limit of 5%
for pyrosequencing [34]. All 72 samples were successfully
amplified and subjected to analysis. The PCR product has
an estimated size of approximately 120 base pairs. Figure 1
shows representative pyrograms of BRAF p.V600E (G),
p.V600K (H) and p.V600R (I) mutations. Only pyrograms
showing peak heights of >/=30 relative fluorescent units
(RLU) were evaluated. Result interpretation was once per-
formed by visual inspection with different sequences to
analyze and in some samples with a mutation in codon
600 using the provided plug-in tool (Qiagen).
Concerning the p.V600E mutation pyrosequencing
showed a higher sensitivity than Sanger sequencing.
Pyrosequencing detected the p.V600E mutation down to
5% mutated alleles in a background of wildtype alleles but
with values for the relative fluorescent units close to our
threshold of 30. Sanger sequencing, HRM and the cobas®BRAF V600 test failed to detect this mutation as described
above. Immunohistochemistry was scored positively as 2+.
Interestingly, NGS showed a 2% allele frequency for
p.V600E in this case being under the cutoff defined for
our study (case 30).
The therascreen® BRAF Pyro Kit sequences in the re-
verse direction starting at codon 600 of the BRAF gene.
Therefore, mutations downstream of codon 600 will be
identified either as false-negative wildtype samples or as
false-positive p.V600E samples. According to COSMIC
database (Catalogue of Somatic Mutations in Cancer,
Dec 2013) 1.4% of mutations are consequently not de-
tected [6]. In our study, three cases were falsely detected
as p.V600E mutation showing once a p.K601E, once a
p.V600K and once a p.[V600E(;)K601E] double mutation
using Sanger sequencing and NGS (case 41, 36 and 25,
respectively, Additional file 1). If these patients are treated
with vemurafenib they may develop keratocanthoma and
squamous-cell carcinoma caused by treatment with
supposable limited clinical benefit [35,36].
Furthermore, as the read length of the pyrosequencing
kit is optimized for the detection of p.V600E mutation,
the peak height can be misinterpreted in the regions up-
stream of codon 600. Two cases that were wildtype using
Sanger sequencing and NGS and showed borderline results
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with a mutation frequency of 8 and 14% (case 29 and 39,
Additional file 1) analyzed by the first sequence to analyze.
A third case (case 31, Additional file 1) could not be ampli-
fied by Sanger sequencing and HRM but was p.G596R
mutated using pyrosequencing (7% allele frequency). Com-
puted analysis with a second sequence to analyze of all
three samples showed no mutation in the pyrograms
reinforcing the wildtype result of the other methods. A
further case (case 32) exhibited a p.L597R mutation using
Sanger sequencing and NGS (8% allele frequency) but the
pyropgram showed a p.G596R mutation with an allele fre-
quency of 28%. The sequence to analyze and the dispension
order used are not designed to detect mutations in codon
597. The mutated nucleotide is therefore incorporated
at the wrong position of the pyrogram resulting in an
incorrect mutation calling.
Thus, pyrosequencing showed a specificity of 90% for
the detection of all mutations in our preselected cohort
(Table 1). According to the manufacturer the therascreen®
BRAF Pyro Kit should only be used for mutations in
codon 600 of the human BRAF gene. Regarding only the
hotspot codon 600 pyrosequencing exhibited a specificity
of 94.6%.
If using the therascreen® BRAF Pyro Kit for the detec-
tion of additional mutations the results should be cri-
tically considered especially concerning mutations in
codon 597, 596 and 594 of the BRAF gene. This is in
concordance with Gong et al., 2010 showing continuous
loss of signal intensities using pyrosequencing when se-
quencing towards increased read length [37]. Moreover,
the interpretation of complex mutations (e.g. double mu-
tations) is prone to errors as only the ratio of the peak
heights vary. In the study of Shen and Qin (2012) a
p.V600K mutation was overlooked by visual inspection
but was detected using pyrosequencing data analysis soft-
ware [38]. Using software tools and a customer designed
assay set-up can avoid such problems [39,40]. Besides, it
allows the detection of a broader spectrum of mutations
[40,41] and reduces the costs down to one-quarter.
Allele specific PCR
The cobas® 4800 BRAF V600 test is the only CE-IVD
marked test used in this study. The CE-IVD mark indi-
cates that this test meets essential requirements regarding
safety, health and environmental protection.
60 out of 82 tumor samples were analyzed with the
cobas® BRAF V600 test (Table 1). All samples showed a
valid result (100%). The allele specific PCR used in this
test generates an amplicon of 116 base pairs containing
codon 600 in exon 15 of the BRAF gene. Amplification
curves are shown only for the mutant and the wildtype
control but not for the samples analyzed and a non-
template control is not provided. Data are analyzed whenmutant and wildtype controls have a “valid” status. A re-
port is generated automatically and results can be distin-
guished between “mutation detected” and “mutation not
detected”. This test is specific for the p.V600E mutation
with a reported sensitivity of ≥5% mutated alleles in a
background of wildtype alleles [42]. Limit of detection in
our preselected cohort was 7% mutant alleles in a back-
ground of wildtype alleles (Table 1).
36 of 37 p.V600E mutations were detected with the cobas®
BRAF V600 test (97.2% sensitivity). One case with a border-
line frequency of 5% of mutated alleles using pyrosequencing
(Figure 3) could not be detected. But it should be taken into
account that we extracted the DNA with our standard in-
house method and not with the recommended kit. This may
influence the test results. Furthermore, the marked area on
the HE-stained slide contained many lymphocytes diluting
the p.V600E alleles. Curry et al. showed an even lower limit
of detection of 4.4% mutated alleles per 1.25 ng/μl on FFPE
tissues for the p.V600E mutation [43]. In contrast, Lade-
Keller et al. performed a dilution series of p.V600E mutated
DNA followed by analysis on the cobas® 4800 BRAF V600
test. This test was not able to detect a p.V600E mutation on
the dilution point that theoretically contained 10% mutant
alleles [33].
Analysis have shown cross reactivity with p.V600E2 (>65%
allele frequency), p.V600K (>35%) and p.V600D (>10%)
but not with p.V600R mutation [43,44]. In our cohort, the
cobas® BRAF V600 test showed cross reactivity five times
in p.V600K mutated samples containing 59, 61, twice 62
and 64% of mutated alleles using pyrosequencing. One
p.V600K mutation with a frequency of 57% that is above the
described cross reactivity, was not detected by the cobas®
4800 BRAF V600 test.
Furthermore, several additional cases with a mutation
frequency below the described limit of detection were
missed in our study: case 9 showed a frequency of 6.6%
for p.V600K, case 36 25% for the same mutation and
case 24 an allele frequency of 46% for the p.V600E2
mutation (Additional file 1). Case 3, 33 and 38 showed
a mutation frequency of 37, 42 and 39% for
p.V600R mutation that can not be detected by this kit.
This makes an overall failure rate of 13.3% in our prese-
lected cohort and a failure rate of mutation located in
codon 600 of 16.3%. Halait et al. even showed that the
cobas® 4800 BRAF V600 test failed to detect 19% of the
mutations occurring in codon 600 of the BRAF gene
[45]. In the study of Curry et al. 82.3% of non-p.V600E
mutations (p.V600K and p.V600R) were not detected
having a tumor content range from 5 - 45% and 14%
median mutant alleles. But recent studies showed that
even patients with p.V600K, p.V600D and p.V600E2 mu-
tation positive melanomas may benefit from therapy with
vemurafenib [7,9,15,46,47]. Furthermore, patients with un-
common mutations as p.V600R and double mutations as
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response based on RECIST (Response Evaluation Criteria
in Solid Tumors) criteria and regression of metastatic le-
sions [15].
As expected, all other mutations evaluated could not
be detected by this method (Tables 1). 3.8% of all muta-
tions detected in malignant melanomas are outside of
codon 600 of the BRAF gene [5]. To date, there are 121
different missense mutations described for BRAF [6].
Especially the p.L597 mutation (frequency 0.5%) plays an
important role as it seems to be associated with sensiti-
vity to MEK inhibitor therapy with TAK-733 [48,49]. To
conclude, in its present set-up, this test is not sufficient
for the European approval of vemurafenib [50].
Next generation sequencing
Next generation sequencing allows the sensitive and
simultaneous detection of various mutations in different
genes in a multiplex approach. 72 out of 82 cases were
subjected to next generation sequencing (NGS). Cover-
age for BRAF exon 15 ranged from 352 to 20174 with a
mean coverage of 5015.4. The coverage of the mutation
site ranged from 118 to 12002 with a mean coverage of
1934.7. Rechsteiner et al. reported in a cohort of 81
colorectal carcinoma samples a coverage rate from 5139
to 17156 [51]. As the threshold of coverage was set to
100 all samples could be analyzed.
The whole mutational spectrum could be detected
by NGS and all cases were analyzed successfully
(Additional file 1). The cut-off value defined for reliable
mutation detection was set as a frequency of 5% mutant
alleles. With this cut-off all but one mutation were analyzed
correctly (98.6% sensitivity). Case 30 (Figure 3) showed only
a 2% mutant allele frequency in the Integrative Genomic
Viewer [6]. Coverage rate using NGS was very low with
181 which may have influenced the results obtained. In
the whole cohort the lowest frequency of mutant alleles
detected with NGS was 7% (Additional file 1). This makes
a specificity of 100% for NGS but a sensitivity of 98.6%
(Table 1).
NGS is characterized by a high working load with a lot
of hands-on time and high costs. These disadvantages
are compensated by the multiplexing possibilities, the
broad spectrum of mutations detected and the high sen-
sitivity. Recent publications state that almost 75% of can-
cer gene variations may be missed by an approach
analyzing only hotspot mutations [52].
The establishment of this rather new method for rou-
tine diagnostic is an ongoing process. The expertise in
computational biology required to perform clinical NGS
is significantly higher than for any other of the estab-
lished methods. Especially, the result interpretation is
challenging: Where to define the cut-off value for a reli-
able mutation, which spectrum of mutations to report,how to validate and to report the results, how to handle
the massive data generated? Standardization and valid-
ation of the test procedure and the data interpretation,
cost reduction and getting to know the pitfalls of this
method are the challenges of the future.
Immunohistochemistry
Immunohistochemistry (IHC) is characterized by a fast
and cheap performance and allows the detection of
even small amounts of tumor cells harboring the spe-
cific antigen. 49 of the 82 samples were subjected
to immunohistochemistry. Staining was homogenous
within the tumor cells as shown by other groups before
[53]. Figure 1 shows representative immunohistochemical
stainings of p.V600E mutation (J) and p.V600K mutation
(K) both in a melanoma sample and p.V600R mutation
(L) of a colorectal tumor.
Staining with the p.V600E specific monoclonal antibody
detected all evaluated p.V600E mutations (100%). 22 of
these p.V600E mutated samples were melanoma and two
were colorectal tumors. Colomba et al. described in con-
trast a IHC failure rate of 7.2% in a cohort of 111 cases
[24] due to equivocal staining.
Furthermore, case 25, showing a double mutation in
codon 600 and codon 601 of the BRAF gene was scored
negative in IHC (Additional file 1). This is in concordance
with the study of Skorokhod et al. (2012) who could
not detect the double mutation with the monoclonal
VE1 antibody either [54]. Eight cases with non-p.V600E
mutation were scored as 1+ and therefore negative in the
IHC (p.V600K, p.L597R/S, p.E586K and p.D594N). Like for
the cobas® 4800 BRAF V600 test this p.V600E specificity
constitutes the major limitation of the IHC for routine
diagnostics as a single test.
However, the IHC was not completely specific for the
p.V600E mutation as cross reactivity was observed in one
case with a p.V600R mutation that was scored as 2+
(Table 1). This is in contrary to most other studies report-
ing no cross reactivity with non-p.V600E mutations
[54-56]. Only Heinzerling et al. (2013) found for one sam-
ple an immunohistochemical cross reactivity with p.V600K
mutation [57]. Therefore, in our study this method is char-
acterized by 100% sensitivity but only 98% specificity
(Table 1). Long et al. showed a sensitivity of 97% and a spe-
cificity of 98% in a cohort of 100 samples [56].
One case of our study highlighted the importance of
immunohistochemical staining prior to DNA extraction
for mutational analysis. Case 7 was wildtype using Sanger
sequencing, HRM, and cobas® BRAF V600 test in the first
extraction. NGS showed a p.V600E mutation with a 3%
allele frequency being under our defined threshold. Sec-
tions for IHC were cut after the molecular analysis and
results were positive with a score of 2+ by a senior path-
ologist (H. U. S.). Tumor content increased only slightly
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a second extraction was performed and analysis was
repeated. The second extract showed a p.V600E mutation
using Sanger sequencing, HRM, NGS as well as cobas®
BRAF V600 test (Figure 4).
In general, Sanger sequencing needs 2 – 4 working days
to produce a report. In contrast, HRM is time and cost sav-
ing and a major advantage is the prevention of contamina-
tions as HRM is a close-tube process [58,59]. But it only
serves as screening method not giving the exact mutational
status. Advantages of pyrosequencing are that it is more
sensitive than Sanger sequencing (5% versus 6.6% in our
cohort) and the amount of work is lower compared to
Sanger sequencing hence no clean up steps of the PCR-
products is needed [34,40] but result interpretation is moreFigure 4 Effects of different extracts on the same sample. DNA from a
results using Sanger, HRM and NGS (3% mutant allele frequency). In contra
p.V600E mutation with all evaluated methods. Sanger: Sanger sequencing,
sequencing, IHC: immunohistochemistry.prone to errors. The cobas® 4800 BRAF V600 test is charac-
terized by an easy and fast performance with a low amount
of work. Costs are medium compared to the other eva-
luated methods (Table 1). Immunohistochemistry (IHC) is
characterized by a fast and cheap performance and allows
the detection of even small amounts of tumor cells harbor-
ing the specific antigen but is limited to the detection of
p.V600E mutations. NGS should be carefully validated to
implement this method into routine diagnostics. At the
moment it is only financially feasible when the full capacity
of the device is used.
Conclusion
To conclude, this is so far the only study comparing these
five molecular methods with immunohistochemistry. Wemelanoma sample (case 7) was extracted and showed wildtype
st, immunohistochemistry was positive. The second extract exhibited a
HRM: high resolution melting analysis, NGS: next generation
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tool is a reliable method for BRAF mutation analysis with
a limit of detection of 6.6%. However, this method has to
be replaced by faster and more cost effective methods.
The cobas® 4800 BRAF V600 test has limited utilization as
it detects only p.V600E mutations losing 16.3% of patients
eligible for a therapy with vemurafenib. The pyrosequencing
approach showed in fact the highest sensitivity in our
preselected cohort with a limit of detection of 5%
mutant alleles but exhibited the lowest specificity with
90% and is prone to errors without using customer
designed set-up. In their present set-up, the cobas®
4800 BRAF V600 test as well as the therascreen® BRAF
Pyro Kit are therefore not sufficient for the European
approval of vemurafenib because there is a therapeutic
option for melanoma patients with any mutation in codon
600 of the BRAF gene [50]. Therefore, we suggest a com-
bination of VE1 antibody staining and HRM for p.V600E
mutation analysis combining the lowest detection limit
with a fast, reliable method with 100% sensitivity for rou-
tine diagnostics at the moment.
In the near future and with growing experiences, it is
an inevitable fact that NGS will replace all established
methods for molecular diagnostics. This is based on the
high sensitivity and multiplexing options of this method
allowing to generate a molecular profile of each tumor
sample analyzed.Additional file
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